Jakarta, July 4 -- Indonesia is aiming to become an Asia-Pacific hub for Advanced Therapy Medicinal Products (ATMP) by expanding the clinical application of stem cell therapy through the implementation of Good Manufacturing Practices (GMP).

The Head of the Food and Drug Authority (BPOM), Taruna Ikrar, said the ambition is driven by the rapid global growth of gene therapy, cell therapy, and ribonucleic acid-based therapies. He noted that 4,164 ATMPs are currently under development worldwide, with 148 already approved in various countries.

Speaking in Jakarta on Saturday, Ikrar said the global ATMP market is projected to rise sharply from US$41.46 billion in 2026 to US$86.76 billion in 2031.

"This trend shows how regenerative medicine is...